FDA expands pediatric indication for Rinvoq

The U.S. Food and Drug Administration has expanded indications for AbbVie’s Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA).

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup